Kumar Rajat NAGENDRA, Gunvant VAİSHNAV, Anjali SONİ, Kalpana DAVE

Risk of Malignancy Index in the Pre-Operative Evaluation of Patients with Adnexal Masses

The aim of this study is to evaluate use of RISK of MALIGNANCY INDEX (RMI) in primary evaluation of adnexal masses without clear evidence of malignancy, by combining serum CA 125 levels, USG score and menopausal status. It is a cross sectional study conducted at Department of gynaec- oncology, Gujarat Cancer and Research Institute, Ahmedabad. A total of 40 women aged 20 to 65 years with ultrasound diagnosed adnexal masses, and serum measurement of cancer-associated antigen CA-125 levels, were studied. They all had surgical exploration (laparotomy) between May 2005 to July 2007 .The RMI was based on menopausal status, ultrasound morphology of adnexal masses and absolute level of serum CA-125. RMI cut-off of 200 was chosen. The various testing methods were evaluated for sensitivity, specificity, positive and negative predictive values. The best performance was with a RMI at a cut-off of 200 with a sensitivity of 66.66%, specificity of 63.15%, positive predictive value of 66.66% and negative predictive value of 65.15% to diagnose malignancy. When RMI was used, it is better in detecting benign tumour and malignant tumour rather than individual component. RMI to be a valuable, reliable and applicable method in primary evaluation of patients with adnexal masses, and a usable method for referral of advanced neoplasia to a more complex healthcare unit

PDF

___

1. Odukogbe AA, Adebamowo CA, Ola B, Olayemi O, Oladokun A, Adewole IF, Omigbodun OA, Aimakhu CO, Okunlola MA, Fakulujo O, Oluyemi FA. Ovarian cancerin Ibadan: Characteristics and management. J Obstet Gynaecol. 2004;24(3):294- 7.

2. Gillis CR, Hole DJ, Still RM, Davis J, Kaye SB. Medical audit, cancer registration, and survival in ovarian cancer. Lancet. 1991;337(8741):611-2.

3. Finkler NJ, Benacerraf B, Lavin PT, Wojciechowski C, Knapp RC. Comparison of serum CA-125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses. Obstet Gynecol. 1988;72(4):659-64.

4. Vasilev SA, Schlaerth JB, Campeau J, Morrow CP. Serum CA-125 levels in preoperative evaluation of pelvic masses. Obstet Gynecol. 1988;71(5):751-6.

5. Zanaboni F, Vergadoro F, Presti M, Gallotti,Lombardi F,Bolis G,Tumour antigen CA125 as a marker of ovarian epithelial carcinoma.Gynecol Oncol. 1987; 28(1): 61-7.

6. Zurawski VR, Knapp RC, Einhorn N, Kenemans P, Mortel R, Ohmi K, Bast RC Jr, Ritts RE Jr, Malkasian G. An initial analysis of preoperative of serum CA125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol. 1983;30(1):7-14.

7. Fures R,Bukovic D,Hodek B,Klaric B,Herman R,Grubisic G.Preoperative tumour marker CA125 levels in relation to epithelial ovarin cancer stage. Coll Antrpol. 1999;23(1):189-94.

8. Maggino T, Gadducci A, D'Addario V, Pecorelli S, Lissoni A, Stella M, Romagnolo C, Federghini M, Zucca S, Trio D, et al.Prospective multi centre study on CA125 in post menopausal pelvic masses. Gynaecol. 1994;54(2):117-23.

9. Requard CK, Mettler FA Jr, Wicks JD. Preoperative sonography of malignant ovarian neoplasm. Am J Roentgenol. 1981;137(1):79-82.

10. Menon U, Talaat A, Rosenthal AN, Macdonald ND, Jeyerajah AR, Skates SJ, Sibley K, Oram DH, Jacobs IJ. Performance of USG as second line test to13serum 125 in ovarian cancer. BTOG. 2000;107(2):165-9.

11. DiSantis DJ,Scatariage JC,Kemp G,Given FT,Hsiu JG,Cramer MS.A prospective evaluation of transvaginal sonography for detection of ovarian disease. Am J Roentgenol. 1993;161(1): 91-4.

12. Tingulstad S1, Hagen B, Skjeldestad FE, Onsrud M, Kiserud T, Halvorsen T, Nustad K.Evaluation of riskof malignancy index based on serum CA 125 ultrasound findings and menopausal status in the preoperative diagnosis of pelvic masses. Br J Obstet Gynecol. 1996;103(8):826-31.

13. Tingulstad S, Hagen B, Skjeldestad FE, Halvorsen T, Nustad K, OnsrudM. The risk of malignancy index to evaluate potential ovarian cancers in local hospitals. Br J Obstet Gynecol 1999; 93(3):448-52.

14. Andersen ES, Knudsen A, Rix P, Johansen B. Risk of malignancyin the preoperative evaluation of patients with adnexal masses. Gynecol Oncol 2003; 90(1): 109-12.

15. Bailey J1, Tailor A, Naik R, Lopes A, Godfrey K, Hatem HM, Monaghan J. Risk of malignancy index for referral of ovarian cancer cases to a tertiary centre: Does it identify the correct cases? Int J Gynecol cancer 2006;16(1):30-4.

16. Ma S, Shan K, Lang J. A risk of malignancy index in preoperative diagnosis of ovarian cancer. Chin Med J (Engl). 2003;116(3):396-9.

17. Torres JC, Derchain SF, Faundes A, Gontijo RC, Martinez EZ, Andrade LA. Risk of malignancy index in preoperative evaluation (p) of clinically restricted ovarian cancer. Sao Paulo Med J 2002; 120(3):72-6.

18. Risum S1, Høgdall C, Loft A, Berthelsen AK, Høgdall E, Nedergaard L, Lundvall L, Engelholm SA.The diagnostic value of PET/CT for primary ovarian cancer. A prospective study.Gynecol Oncol 2007; 105(1): 145-9.

19. Makhija S, Howden N, Edward R, Kelley J, Townsend DW, Meltzer CC. Positron emission tomography imaging for detection of recurrent ovarian and fallopian tube carcinoma:A retrospective review. Gynecol Oncol 2002;85(1):53-8.

20. Rufford RD, Jacobs IJ. Ovarian cysts in postmenopausal women. RCOG Green-Top Guidel 34: 1–8.